Logotype for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Sichuan Kelun-Biotech Biopharmaceutical (6990) investor relations material

Sichuan Kelun-Biotech Biopharmaceutical H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
H1 2025 earnings summary18 Aug, 2025

Executive summary

  • Revenue for the first half of 2025 was RMB950.4 million, down 31.3% year-over-year, mainly due to lower milestone payments from license and collaboration agreements.

  • Net loss for the period was RMB145.2 million, compared to a profit of RMB310.2 million in the prior year; adjusted loss was RMB69.4 million.

  • Achieved significant commercialization milestones with multiple product launches and regulatory approvals in oncology and immunology, including first-in-class ADCs and mAbs for lung, breast, and nasopharyngeal cancers.

  • Expanded global clinical collaborations, notably with MSD, and out-licensed key assets for international development.

  • Included in major global equity indexes and completed a substantial H-share follow-on financing round.

Financial highlights

  • Gross profit for 1H25 was RMB660.0 million, with gross margin decreasing to 69.4% from 77.9% year-over-year.

  • R&D expenses for 1H25 totaled RMB611.5 million, down 6.3% year-over-year; selling and distribution expenses rose 334.8% to RMB178.9 million.

  • Cash and financial assets totaled RMB4,527.8 million as of June 30, 2025, up 47.2% from year-end 2024.

  • Net cash generated from financing activities in 1H25 was RMB1,774.4 million, mainly from a June 2025 share placement.

  • No borrowings; gearing ratio not applicable due to excess cash over liabilities.

Outlook and guidance

  • Focus on advancing differentiated pipelines targeting high unmet medical needs, especially in oncology and non-oncology diseases.

  • Plans to launch trastuzumab botidotin in China and file NDA for A400 in H2 2025.

  • Continued investment in R&D, AI-enabled drug discovery, and expansion of global partnerships.

  • Ongoing efforts to optimize commercialization strategies and expand market access, with expectations for higher sales in the second half, especially from lung cancer indications.

  • Anticipates operational costs to decrease as products gain medical insurance coverage.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Sichuan Kelun-Biotech Biopharmaceutical earnings date

Logotype for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
H2 202523 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Sichuan Kelun-Biotech Biopharmaceutical earnings date

Logotype for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
H2 202523 Mar, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based company engaged in the research, development, and manufacturing of biopharmaceutical products. The company focuses on innovative therapeutics across various medical fields, including oncology, infectious diseases, and autoimmune disorders. It develops biologic drugs and biosimilars, utilizing advanced biotechnological platforms to address unmet medical needs. Sichuan Kelun-Biotech serves both domestic and international pharmaceutical markets. The company is headquartered in Chengdu, China, and its shares are listed on the Hong Kong Stock Exchange.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage